Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

How Boehringer Ingelheim is buttressing its US business

18:36
 
Share
 

Manage episode 512817348 series 3386301
Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the lucrative American market.

In this week’s episode of “The Top Line,” we dive into Boehringer Ingelheim’s latest regulatory successes, two crucial launches, and the German company’s expanding commercialization push in the U.S.

Fierce Pharma’s Fraiser Kansteiner sits down with Brian Hilberdink—who joined Boehringer as president of U.S. human pharma in February—to discuss his game plan to further unlock the American market and capitalize on key BI green lights in idiopathic pulmonary fibrosis and lung cancer.

To learn more about the topics in this episode:

See omnystudio.com/listener for privacy information.

  continue reading

100 episodes

Artwork
iconShare
 
Manage episode 512817348 series 3386301
Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the lucrative American market.

In this week’s episode of “The Top Line,” we dive into Boehringer Ingelheim’s latest regulatory successes, two crucial launches, and the German company’s expanding commercialization push in the U.S.

Fierce Pharma’s Fraiser Kansteiner sits down with Brian Hilberdink—who joined Boehringer as president of U.S. human pharma in February—to discuss his game plan to further unlock the American market and capitalize on key BI green lights in idiopathic pulmonary fibrosis and lung cancer.

To learn more about the topics in this episode:

See omnystudio.com/listener for privacy information.

  continue reading

100 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play